Cel-Sci Corp (CVM) 1.11 $CVM
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 47.47 (+0.03), NWBO: 7.63 (-0.19), ZIOP: 13.89 (-0.11), PCYC: 257.85 (-0.21), CVM: 1.11 (unch), PFE: 34.25 (+0.10), CLDX: 30.38 (-1.40), IMGN: 7.44 (-0.48), BMY: 67.76 (-0.56), RIGL: 3.45 (-0.06), INO: 9.09 (-0.36), KITE: 71.89 (-1.62), LH: 126.80 (+0.54), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Myocarditis Pipeline Review 2015 - 2 Companies & 6 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mbghnx/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - CEL-SCI Corporation - Novartis AG Drug Profiles - CEL-1000 - Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Cell Therapy to Target Flt3L for Autoimmune Myocarditis - Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - OBR-5340 - Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis For more information visit http://www.researchandmarkets.com/research/mb...yocarditis
CVM: 1.11 (unch), NVS: 101.68 (+1.81)
CEL-SCI Corp (CVM) Falls: Stock Goes Down 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:03AM CDT
This slump shouldn’t be too much of a surprise to investors, as CEL-SCI Corp (CVM) has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days
CVM: 1.11 (unch), ABAX: 65.61 (+1.33)
CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:21AM CST
CEL-SCI Corporation (CVM) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
CVM: 1.11 (unch), AFFX: 12.87 (-0.07)
CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Mar 03, 7:15AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This follows January's prior record. A total of 377 patients have been enrolled in the world's largest Phase III study in head and neck cancer as of February 28, 2015.
CVM: 1.11 (unch)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:15AM CST
CVM: 1.11 (unch), NBG: 1.34 (+0.14), NXPI: 108.03 (+2.71), LL: 28.51 (-0.84), LPI: 11.98 (+0.21), WBAI: 11.06 (+1.08), ANFI: 9.66 (-0.15), SYN: 2.59 (+0.06), GDP: 3.12 (+0.09), CYCC: 0.98 (+0.02), EGO: 5.09 (+0.21), CYTX: 1.19 (-0.03), TCPI: 2.35 (-0.01), OHRP: 9.26 (-0.09), ATHX: 3.20 (+0.03), ARCP: 10.09 (+0.23), FSL: 43.39 (+0.82), PCRX: 97.64 (-0.08), NAVI: 20.70 (+0.03), SMRT: 12.59 (+0.19)
Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
PR Newswire - Mon Mar 02, 7:35AM CST
Cutting-edge biotech & nutraceutical products, science-based pharmaceuticals and healthy whole food nutrition products reveal technological advancements are in growing demand for treatments of lifestyle related disorders such as hyperglycemia, obesity, insulin level issues and other serious illnesses and health concerns. Nutraceutical and Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: RIBT), Amira Nature Foods Ltd. (NYSE: ANFI), CEL-SCI Corporation (NYSE: CVM), Mondelez International, Inc. (NASDAQ: MDLZ) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).
HLF: 42.10 (+4.16), RIBT: 4.38 (-0.12), MDLZ: 34.74 (+0.08), CYCC: 0.98 (+0.02), CVM: 1.11 (unch), ANFI: 9.66 (-0.15)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 475.98 (+42.33), BMRN: 125.17 (-2.32), CVM: 1.11 (unch), MDGN: 8.00 (-0.45), PFE: 34.25 (+0.10), SGMO: 17.63 (-0.91), RPRX: 8.98 (-0.26), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17), SGEN: 38.86 (-0.83), TEVA: 62.10 (+0.55), ARIA: 8.69 (-0.28), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial
Business Wire - Thu Feb 19, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced the Ministry of Health Malaysia has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Malaysia. Malaysia is the 20th country to approve CEL-SCI's Phase III trial, which now has over 350 patients enrolled.
CVM: 1.11 (unch)
CEL-SCI to Present at 3rd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Wed Feb 18, 7:01AM CST
CEL-SCI Corporation (NYSE MKT:CVM), a late-stage oncology company, announced that Geert Kersten, Chief Executive Officer, will be presenting at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on Monday, February 23, 2015 at 3:30 p.m. The Forum is being held at the New York Academy of Sciences.
CVM: 1.11 (unch)
Cel-Sci Is Closer To The Finish Line, But Skip This Stock For Now
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 12:23PM CST
CVM: 1.11 (unch)
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Wed Feb 11, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines. Three hospitals in the Philippines are expected to join the study.
CVM: 1.11 (unch)
CEL-SCI posts higher net loss of USD7.845m for Q1 2015
M2 - Mon Feb 09, 5:43AM CST
Immunotherapeutic company CEL-SCI (NYSE MKT:CVM) stated on Friday that its net loss was USD7.845m (USD0.09 per basic common share) for the first quarter ended 31 December 2014.
CVM: 1.11 (unch)
Cel-Sci EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:52PM CST
CVM: 1.11 (unch)
CEL-SCI Corporation Reports First Quarter 2015 Financial Results
Business Wire - Fri Feb 06, 3:40PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2014.
CVM: 1.11 (unch)
CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 05, 7:03AM CST
CEL-SCI Corporation (NYSE MKT:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:00 p.m. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
CVM: 1.11 (unch)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 1.11 (unch), PSTI: 2.80 (-0.05), ORMP: 3.93 (-0.05)
CeL-Sci's Innovative Cancer Killer Featured in February Issue of PharmaVOICE
ACCESSWIRE - Mon Feb 02, 8:32AM CST
LOS ANGELES, CA / ACCESSWIRE / February 3, 2015 / On the heels of announcing another record monthly patient enrollment in its Phase III Head and Neck Cancer Trial, Geert Kersten, the CEO of CEL-SCI Corporation (NYSE MKT:CVM) is featured in the February issue of PharmaVOICE, a print publication for life-sciences executives and other healthcare-service related professionals.
CVM: 1.11 (unch)
CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Mon Feb 02, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in January it enrolled 24 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a record month for enrollment. 352 patients have been enrolled in the study as of January 31, 2015.
CVM: 1.11 (unch)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 47.47 (+0.03), NWBO: 7.63 (-0.19), ZIOP: 13.89 (-0.11), PCYC: 257.85 (-0.21), CVM: 1.11 (unch), PFE: 34.25 (+0.10), CLDX: 30.38 (-1.40), IMGN: 7.44 (-0.48), BMY: 67.76 (-0.56), RIGL: 3.45 (-0.06), INO: 9.09 (-0.36), KITE: 71.89 (-1.62), LH: 126.80 (+0.54), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Myocarditis Pipeline Review 2015 - 2 Companies & 6 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mbghnx/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - CEL-SCI Corporation - Novartis AG Drug Profiles - CEL-1000 - Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Cell Therapy to Target Flt3L for Autoimmune Myocarditis - Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - OBR-5340 - Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis For more information visit http://www.researchandmarkets.com/research/mb...yocarditis
CVM: 1.11 (unch), NVS: 101.68 (+1.81)
CEL-SCI Corp (CVM) Falls: Stock Goes Down 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:03AM CDT
This slump shouldn’t be too much of a surprise to investors, as CEL-SCI Corp (CVM) has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days
CVM: 1.11 (unch), ABAX: 65.61 (+1.33)
CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:21AM CST
CEL-SCI Corporation (CVM) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
CVM: 1.11 (unch), AFFX: 12.87 (-0.07)
CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Mar 03, 7:15AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This follows January's prior record. A total of 377 patients have been enrolled in the world's largest Phase III study in head and neck cancer as of February 28, 2015.
CVM: 1.11 (unch)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:15AM CST
CVM: 1.11 (unch), NBG: 1.34 (+0.14), NXPI: 108.03 (+2.71), LL: 28.51 (-0.84), LPI: 11.98 (+0.21), WBAI: 11.06 (+1.08), ANFI: 9.66 (-0.15), SYN: 2.59 (+0.06), GDP: 3.12 (+0.09), CYCC: 0.98 (+0.02), EGO: 5.09 (+0.21), CYTX: 1.19 (-0.03), TCPI: 2.35 (-0.01), OHRP: 9.26 (-0.09), ATHX: 3.20 (+0.03), ARCP: 10.09 (+0.23), FSL: 43.39 (+0.82), PCRX: 97.64 (-0.08), NAVI: 20.70 (+0.03), SMRT: 12.59 (+0.19)
Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
PR Newswire - Mon Mar 02, 7:35AM CST
Cutting-edge biotech & nutraceutical products, science-based pharmaceuticals and healthy whole food nutrition products reveal technological advancements are in growing demand for treatments of lifestyle related disorders such as hyperglycemia, obesity, insulin level issues and other serious illnesses and health concerns. Nutraceutical and Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: RIBT), Amira Nature Foods Ltd. (NYSE: ANFI), CEL-SCI Corporation (NYSE: CVM), Mondelez International, Inc. (NASDAQ: MDLZ) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).
HLF: 42.10 (+4.16), RIBT: 4.38 (-0.12), MDLZ: 34.74 (+0.08), CYCC: 0.98 (+0.02), CVM: 1.11 (unch), ANFI: 9.66 (-0.15)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 475.98 (+42.33), BMRN: 125.17 (-2.32), CVM: 1.11 (unch), MDGN: 8.00 (-0.45), PFE: 34.25 (+0.10), SGMO: 17.63 (-0.91), RPRX: 8.98 (-0.26), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17), SGEN: 38.86 (-0.83), TEVA: 62.10 (+0.55), ARIA: 8.69 (-0.28), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial
Business Wire - Thu Feb 19, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced the Ministry of Health Malaysia has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Malaysia. Malaysia is the 20th country to approve CEL-SCI's Phase III trial, which now has over 350 patients enrolled.
CVM: 1.11 (unch)
CEL-SCI to Present at 3rd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Wed Feb 18, 7:01AM CST
CEL-SCI Corporation (NYSE MKT:CVM), a late-stage oncology company, announced that Geert Kersten, Chief Executive Officer, will be presenting at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on Monday, February 23, 2015 at 3:30 p.m. The Forum is being held at the New York Academy of Sciences.
CVM: 1.11 (unch)
Cel-Sci Is Closer To The Finish Line, But Skip This Stock For Now
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 12:23PM CST
CVM: 1.11 (unch)
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Wed Feb 11, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines. Three hospitals in the Philippines are expected to join the study.
CVM: 1.11 (unch)
CEL-SCI posts higher net loss of USD7.845m for Q1 2015
M2 - Mon Feb 09, 5:43AM CST
Immunotherapeutic company CEL-SCI (NYSE MKT:CVM) stated on Friday that its net loss was USD7.845m (USD0.09 per basic common share) for the first quarter ended 31 December 2014.
CVM: 1.11 (unch)
Cel-Sci EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:52PM CST
CVM: 1.11 (unch)
CEL-SCI Corporation Reports First Quarter 2015 Financial Results
Business Wire - Fri Feb 06, 3:40PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2014.
CVM: 1.11 (unch)
CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 05, 7:03AM CST
CEL-SCI Corporation (NYSE MKT:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:00 p.m. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
CVM: 1.11 (unch)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 1.11 (unch), PSTI: 2.80 (-0.05), ORMP: 3.93 (-0.05)
CeL-Sci's Innovative Cancer Killer Featured in February Issue of PharmaVOICE
ACCESSWIRE - Mon Feb 02, 8:32AM CST
LOS ANGELES, CA / ACCESSWIRE / February 3, 2015 / On the heels of announcing another record monthly patient enrollment in its Phase III Head and Neck Cancer Trial, Geert Kersten, the CEO of CEL-SCI Corporation (NYSE MKT:CVM) is featured in the February issue of PharmaVOICE, a print publication for life-sciences executives and other healthcare-service related professionals.
CVM: 1.11 (unch)
CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Mon Feb 02, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in January it enrolled 24 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a record month for enrollment. 352 patients have been enrolled in the study as of January 31, 2015.
CVM: 1.11 (unch)
